Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AbbVie, absenteeism, Aid, anesthesiologist, Attending, axatilimab, belief, Biden, bifurcated, bifurcation, Bio, biostatistic, carryback, caution, Center, cGVHDa, circumstance, cleaning, closure, constitutionality, COVID, Daphne, deprioritize, deprioritized, distancing, doctor, economy, embedded, entosplentinib, Exposition, Eytan, FedEx, forfeited, formation, formatted, fundamental, geopolitical, Hedging, HHS, hospital, Incyte, Inline, Island, JAK, judgement, Kadmon, Kettering, Kura, Lee, magnitude, Medicine, Memorial, methyl, multiorgan, NaN, nationwide, NIH, Northern, pandemic, path, perfect, postal, pronounced, recession, reconsider, remote, remotely, reopen, reprioritization, residence, Rhode, routinely, RSU, score, sequester, shelter, shifting, SIP, situation, Sloan, slowdown, spread, Stein, SYK, tie, today, transferase, truthful, unnecessary, verification, virtual, waived, whichwould, wild, workforce, worsening, xenograft
Removed:
abemaciclib, absence, adhere, administered, Afinitor, alpelisib, antidilution, appointed, arm, ASU, atezolizumab, attributed, bavencio, bladder, BRAF, carcinoma, carry, CDK, circulating, classification, collaborated, colon, colorectal, combining, complementary, concentration, confidentially, confirm, conventional, dabrafenib, damage, Darmstadt, disposition, Dohme, dropping, DSMC, durvalumab, dying, dynamic, eliminate, emergence, ENCORE, endocrine, ensuring, ER, estrogen, evident, exploratory, expression, Faslodex, faster, fatigue, feedback, field, gastrointestinal, Genentech, Germany, GmbH, goal, halted, hematologic, hired, hormonal, Ibrance, immunologic, improve, improved, ipilmumab, Keytruda, KGaA, kinase, Kisqali, leaving, logistical, mammalian, managing, matching, median, Mekinist, melanoma, men, Merck, metastasized, metastatic, microsatellite, mode, modulation, monocyte, MSD, multicenter, nivolumab, NSCLC, observe, occurring, Opdivo, ovarian, overcome, overlapping, palbociclib, pancreatic, pembrolizumab, people, peripheral, Pfizer, PFS, pharmacologic, pharmacology, procuring, progressed, progression, prolong, proper, proportion, prospective, prostate, qualification, radiation, Raf, rapamycin, rationale, reach, reclassification, reclassified, regimen, reliance, relieve, remained, repealing, responding, responsive, retrospective, ribociclib, Richard, risen, Roche, room, sanctioned, Sharp, Shea, shortage, shorten, stable, statistician, stimulation, stopped, stricter, suited, supplying, Tafinlar, tecentriq, TNBC, toxic, trametinib, Treasurer, unexpectedly, unreasonably, unreliable, unresectable, unsafe, utilize, validation, vemurafenib, Verzenio, withdrawing, women, Yervoy, Zelboraf
Filing tables
Filing exhibits
Related press release
Associated SNDX transcripts
SNDX similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-210412, 333-220172, 333-226678, 333-233083, and 333-241654 on Form S-8 and Registration Statement No. 333-233564 on Form S-3 of our report dated March 11, 2021, relating to the financial statements of Syndax Pharmaceuticals, Inc. and subsidiaries appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 11, 2021